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Although most prolactinomas are benign, some are invasive or aggressive. The management of invasive
giant prolactinomas (IGPs) has been an area of controversy. The present study reports the combined
treatment of IGP with surgical excision, low-dose gamma knife radiosurgery (GKRS), and a dopamine
agonist. An enhancing mass at the pituitary fossa with suprasellar extension and invasion of the
cavernous sinus was identiﬁed in two patients. The blood prolactin level was more than 1000 ng/mL in
both patients before treatment. Trans-sphenoidal removal of the tumors was done to reduce tumor
compression on the optic apparatus. Low-dose GKRS was then used to treat the residual tumor with
invasion to the caversinous sinus. The marginal dose was set at 12 and 14 Gy at the 50% and 42% isodose
lines, respectively. A dopamine agonist, cabergoline, was used after GKRS. The tumors were markedly
reduced and hard to be seen in magnetic resonance images. After a follow-up period of more than 3
years, the blood prolactin level returned to normal in one patient without the use of the dopamine
agonist and was nearly normal in the other patient with continuing use of the dopamine agonist.
Treatment combining surgical excision, GKRS, and a dopamine agonist may be a good treatment for IGPs.
To make sure the remission of the disease, the longer follow-up is needed.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
A prolactin-secreting pituitary adenoma, the most common
type of hyperfunctioning pituitary adenoma, accounts for approx-
imately 50e60% of all functional pituitary tumors [1]. Signiﬁcant
advances in the last few decades have contributed to the effective
management of prolactinomas, including pharmacological thera-
pies, microsurgical and endoscopic techniques, and stereotactic
radiosurgery. Giant prolactinomas with cavernous sinus invasion
are a subcategory of prolactinomas. The giant tumor associated
with characteristics of hyperprolactinemia and invasive growth
remains one of the greatest challenges in neurosurgery. Although
they are generally benign, marcroadenomas are locally aggressive.ry, Buddhist Tzu Chi General
n. Tel.:þ88638561825x2040;
).
ddhist Compassion Relief Tzu ChiTumors can invade the surrounding structures such as the
cavernous sinus, sphenoid sinus, and suprasellar optic apparatus.
Dopamine agonists were reported to be able to reduce the tumor
size and to normalize prolactin levels [2e9]. However, some pro-
lactinomas are refractory medically, and a mass effect may
compromise the optic apparatus, resulting in visual impairment
[6,8]. Therefore, combination therapy with surgical excision to
decompress the mass effect followed by focalized radiosurgery and
a low-dose dopamine agonist may be ideal to control a giant pro-
lactinoma. We report successful results in two patients with this
combined treatment.
2. Case reports
2.1. Case 1
A 26-year-old man presented with a 3-month history of head-
ache and dizziness with blurred vision for 1 month. He underwentFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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nously enhancing mass at the pituitary fossa with suprasellar
extension and compression of the optic chiasm (vertical diameter
4.0 cm, lateral diameter 3.2 cm, and anterioposterior diameter
2.4 cm). The tumor invaded the sphenoid sinus and the bilateral
cavernous sinus with encasement of the internal carotid arteries.
Trans-sphenoidal decompression surgery with partial removal of
the tumor was done. The pathology showed a benign prolactinoma.
The blood prolactin level was greater than 1000 ng/mL before and
after this operation. The patient was referred for gamma knife
radiosurgery (GKRS) 3 months after surgery. A combination of
multiple 8-mm and 4-mm isocenters was used to deliver a dose to
the tumor margin of 12 Gy and a maximal dose of 24 Gy. The
treated tumor volume was 21.5 cm3. To avoid the interfere of
radiosurgical effect, a dopamine agonist was not used at least 2
weeks before GKRS. However, cabergoline (Dostinex) 0.5 mg once
per week was given after GKRS. We checked the prolactin level
every 3 months and the dostinex was used if prolactin level is
higher than the normal range. Now, 66 months after radiosurgery,
he has no new clinical symptoms and the prolactin level has
decreased to 3.58 ng/mL without the use of the dopamine agonist.
The tumor has almost disappeared (Fig. 1). The patient continues to
undergo periodic imaging and hormone survey during follow-up.
2.2. Case 2
A 54-year-old woman was referred from another hospital for
a residual pituitary adenoma after two trans-sphenoidal opera-
tions. She had a history of hyperprolactinemia for 20 years and had
irregularly received the dopamine agonist with bromocriptin. She
had presented with a 4-month history of dizziness and blurring of
vision before the ﬁrst trans-sphenoidal surgery. The prolactin levels
were 13,500 ng/mL before and 24,000 ng/mL after the ﬁrst trans-
sphenoidal removal of tumor. After the second operation 11months
later, the prolactin level decreased to 7143 ng/mL. Other pituitary
hormone levels were normal. Clinical examination revealed a rightFig. 1. Case 1. Coronal magnetic resonance images with contrast enhancement obtained in
strating a giant sellar tumor with suprasellar extension and invasion of the cavernous sinus.
months (C), and 51 months (D), demonstrating reduction and near eradication of the tumotemporal hemianopsia. Magnetic resonance imaging showed
residual tumor with a vertical diameter of 5.5 cm, lateral diameter
3.7 cm, and anterioposterior diameter 2.5 cm. The tumor invaded
the right cavernous sinus with encasement of the internal carotid
artery and extension of the suprasellar portion, which slightly
compressed the optic chiasm (Fig. 2). In GKRS, a combination of
four 14-mm, nineteen 8-mm, and twenty-six 4-mm isocenters
were used to deliver a dose of 14 Gy to the tumor margin at the
isodose line of 42% (Fig. 2). The maximal dose was 33 Gy, and the
total treated volume was 28 cm3. Because we consider the possi-
bility of interfering effect by the dopamine agonist, the dopamine
agonist was not used 1 month before GKRS and we started using
cabergoline 0.5 mg twice a week 1 month after GKRS. The blood
prolactin level decreased from more than 1000 ng/mL to 621 ng/
mL. After a 3-year follow-up, it became normal. The tumor was
markedly reduced and hard to be seen in the following magnetic
resonance study (Fig. 3).
3. Discussion
The diagnostic criteria for invasive giant prolactinomas (IGPs)
include (1) tumor diameter larger than 4 cm with invasion of the
cavernous sinus corresponding to Grade III or IV [2,10,11], in the
classiﬁcation system of Knosp and associates; (2) serum prolactin
level greater than 200 ng/mL; and (3) clinical neurological symp-
toms of hyperprolactinemia and mass effect. In our patients, the
tumor size, aggressive invasion of the cavernous sinus, and high
prolactin level ﬁt the criteria for IGPs. However, this pattern is not
the malignant form of a prolactinoma, the aggressive behavior
seems to be an another entity of prolactinoma. Our second patient
had a 20-year history of prolactinemia and microadenoma, which
seems to indicate a tendency to progression. However, in the
report of Ciccarelli et al, the risk of progression from a micro-
adenoma to a macroadenoma was estimated to be only about
4e7% and most observations suggest that aggressive macro-
adenoma may represent a distinct entity [12e15]. At present, therea 26-year-old man. (A) Post-operative, pre-gamma knife radiosurgery image demon-
(BeD) Post-gamma knife radiosurgery magnetic resonance images at 6 months (B), 32
r.
Fig. 2. Case 2. Axial contrast magnetic resonance images with coronal and sagittal reconstruction demonstrating a giant prolactinoma in a 54-year-old woman. The radiosurgical
dose plan is also shown. Four 14-mm, nineteen 8-mm, and twenty-six 4-mm isocenters were used. The 42% isodose line with a 14 Gy margin dose was targeted to the tumor. The
red line is the tumor margin, the yellow line is the 42% isodose line for 14 Gy and the green line is the isodose line for 10 Gy.
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lactinomas [16,17].
The treatment goals of IGPs are as follows: (1) eradication of the
tumor, (2) preservation of normal pituitary function, (3) reduction
of the prolactin level to normal, and (4) prevention of damage to the
regional optic apparatus and hypothalamus. Administration of
a dopamine agonist has shown efﬁcacy and safety in therapy forFig. 3. Case 2. Coronal magnetic resonance images with contrast enhancement obtained
demonstrating a giant sellar tumor with suprasellar extension and bilateral invasion of the ca
30 months (D) after gamma knife radiosurgery, demonstrating reduction and near eradicatthis tumor and some reports even suggest it as the ﬁrst line
treatment for IGPs [2e9]. However, 10e20% of patients are refrac-
tory to medical therapies despite increasing doses. They cannot
tolerate side effects such as nausea, headache, fatigue, orthostatic
hypotension, and depression [6,8]. Although the total removal of
the tumor is not possible after invasion of the cavernous sinus,
surgical decompression with a trans-sphenoidal procedure isin a 54-year-old woman. (A) Post-operative, pre-gamma knife radiosurgery image
vernous sinus. (BeD) Magnetic resonance imaging at 6 months (B), 22 months (C), and
ion of the tumor.
T.-W. Loh et al. / Tzu Chi Medical Journal 23 (2011) 135e138138mandatory for normal visual function in the early stage of visual
ﬁeld impairment. To avoid the damage to the vision in radiosurgery,
it is necessary to have a gap between tumor mass and the optic
apparatus. This surgical decompression is used not only for resto-
ration of visual function but also to avoid the possibility of damage
to the optic apparatus from high marginal dose radiosurgery. In
Pourantan et al’s report, a distance of at least 5 mm between the
tumor margin and the optic apparatus was considered for GKRS
[18]. With such a large gap, a high margin dose, for example 25 Gy,
can be used in some relatively small tumors. Because we used low
margin doses (12e14 Gy) to treat IGPs in our study, the gap clear-
ance could be set as low as 2 mm to limit the dose to the optic
apparatus to 8 Gy. No further vision changes were identiﬁed in our
two patients during follow-up.
In this report, we treated large giant prolactinomas (21.5 cm3
and 28 cm3) with low-dose radiosurgery and maintained a low but
effective dose of a dopamine agonist to control the prolactin level.
We did not use the dopamine agonist at the time of GKRS. We
hypothesized that the higher activity of the prolactin-secreting
tumor cells may have conferred sensitivity to radiosurgery. Landolt
et al and Pouratian et al reported low remission rates in patients
who were on a dopamine agonist at the time of GKRS [18,19].
A dopamine agonist not only reduces prolactin synthesis and
secretion, but also reduces the metabolism and cell cycling of
prolactinomas, which may render them less susceptible to radia-
tion. In contrast, high prolactin levels in IGPs indicate that metab-
olism and cell cycling are high and these tumors may be more
susceptible to a dopamine agonist or even radiation than small
prolactinomas. However, with these treatments, it is difﬁcult to
ascertain the contribution of antisecretory medications to the
observed volumetric tumor control. The continued antisecretory
medication therapy for the duration of follow-up undoubtedly
contributed in part to the long-term volumetric changes observed
in these two cases. Furthermore, it is known that the effects of
radiosurgery are delayed. Lim et al reported a series of 19 patients
with prolactinomas [20]. They found that approximately 1.5 years
was needed to achieve a signiﬁcant decrease in tumor volume and
volume reduction could continue beyond 2 years. This study
supports the notion that a volumetric response in prolactinomas
can continue for years after GKRS. This study shows that combined
therapy, including low-dose GKRS and a dopamine agonist, should
be considered to achieve volumetric tumor control.
There are reasons why we used low marginal doses (12e14 Gy)
to treat IGPs. The tumors were large, 21.5 cm3 in Case 1 and 28 cm3
in Case 2. It is difﬁcult to render a highmargin dose in a tumormass
without involving the adjacent optic apparatus in the high dose.
A radiosurgery dose less than 8 Gy to the optic nerves and chiasm is
generally recommended, although some studies indicate that small
sections of the optic nerve chiasm can tolerate doses of 10e12 Gy
with a very low risk of optic injury [21e26]. We hypothesized that
the higher activity of the prolactin-secreting tumor cells may have
indicated higher sensitivity of the tumor to radiosurgery. Low-dose
radiosurgery may be good enough to shrink these giant tumors.
In this report, a dopamine agonist was not used at the time of
GKRS for not reducing the prolactin-secreting activity, but after
GKRS it was re-started and found effective in the tumor shrinkage.
IGPs are tumors invading the cavernous sinus. Although higher
doses such as 25 Gy or more for the margin dose are suggested to
reach a functional remission of hormone levels, radiation injury to
the cranial nerves has been reported. Furthermore, higher doses
might also lead to a greater risk of radiation-induced hypopituita-
rism [18]. In our cases, we used low-dose radiosurgery anda low-dose dopamine agonist to reach a volumetric reduction, and
no cranial neuropathy was found. We conclude that a multidisci-
plinary approach that includes low-dose radiosurgery and a low-
dose dopamine agonist may beneﬁt patients when extirpation is
not possible.References
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